Deleted
Deleted Member
Posts: 0
|
Post by Deleted on May 1, 2014 12:22:17 GMT -5
How strong is MNKD's patent position. Will there be any time remaining on them with all the delays?
|
|
|
|
Post by sunny3999 on May 1, 2014 12:30:05 GMT -5
I read that the patent could last at least for decades, as Technosphere could be used in several new drugs e.g. Pain disease, Migraine and a lot more...so in that case the patent will renew for each drug from beginning...hope i am right with my explanation...
Just give me feedback if there is a misunderstanding from my side....
|
|
|
|
Post by mdcenter61 on May 1, 2014 12:37:03 GMT -5
Al Mann was very clear in their quarterly CC earlier this year that they do, in fact, have extensions of time due to delays; most of those run well into late 2020's or 2030, as I recall. More than 500 different approved patents, with that many more in approval pipeline, as I recall. Anyone else please correct if I'm wrong.
|
|
|
|
Post by mdcenter61 on May 1, 2014 12:43:34 GMT -5
From February 18 meeting, Al:
One topic we have not really talked about much is our patent position. When MannKind started our clinical trials program for AFREZZA over a dozen years ago, we had the potential for only a handful of patents, and those would have provided protection only until 2020. The [unintelligible] technology and its application in AFREZZA have enormous potential. Recognizing that significance in our intellectual property, our scientists and engineers have worked hard to expand and diversify our patent portfolio.
Today, [Technosphere] technology, including AFREZZA, is protected around the world by dozens of patent families that have produced over 550 issued patents, with another 470 patent applications pending.
Our current longest-lived patents outside the U.S. will expire in 2029 and 2030, but to compensate for [unintelligible] prosecution in the U.S., terms of some of our issued patents have been adjusted and will not expire until 2032.
|
|
